MTOR and lymphoma: Indeed, since mantle cell lymphoma overexpress cyclin D1, a key protein involved in the G1/S transition phase and regulated by mTOR signalling, this lymphoma was the first hematologic disease in which the therapeutic efficiency of mTOR inhibitors was investigated [119].